Keyword: Axovant Sciences
David Hung's decision to join Axovant after selling Medivation to Pfizer for $14 billion now looks more like a gamble that isn't paying off.
Last year, a quiet J.P. Morgan Healthcare Conference meant few deals, few major updates. That set the tone for much of the year on the M&A front.
Axovant’s run of bad news shows no signs of letting up, with negative results in a phase 2b trial spelling the end for lead candidate intepirdine.
Roivant’s Vivek Ramaswamy didn't sugarcoat its Alzheimer’s flop but said his company won't back away from the field.
The deal gives Roivant, Axovant’s parent company, another part-developed, unloved drug to try to turn into a star.
Axovant becomes the latest company to see a major miss in Alzheimer's.
Perrigo CEO Hendrickson will retire after just over a year on the job, Johnson & Johnson has poached Merck exec Mammen to head pharma R&D, and more.
Roivant has launched yet another new biotech, this time focused on urologic disorders
Medivation founder David Hung has become CEO of Axovant, Destiny Pharma tapped Neil Clark as CEO and Allergan hired a finance expert.
Axovant Sciences is capitalizing on the attention it has received from welcoming biotech icon David Hung as its new CEO with a $125 million share offering.